| Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework D Cook, D Brown, R Alexander, R March, P Morgan, G Satterthwaite, ... Nature reviews Drug discovery 13 (6), 419-431, 2014 | 1375 | 2014 |
| Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections E Domenici, DR Willé, F Tozzi, I Prokopenko, S Miller, A McKeown, ... PLoS one 5 (2), e9166, 2010 | 403 | 2010 |
| Quantitative trait loci mapping of three loci controlling morphine preference using inbred mouse strains WH Berrettini, TN Ferraro, RC Alexander, AM Buchberg, WH Vogel Nature genetics 7 (1), 54-58, 1994 | 255 | 1994 |
| Schizophrenia, just the facts: What do we know, how well do we know it? RJ Wyatt, RC Alexander, MF Egan, DG Kirch Schizophrenia Research 1 (1), 3-18, 1988 | 196 | 1988 |
| Treatment of tardive dyskinesia with vitamin E. MF Egan, TM Hyde, GW Albers, A Elkashef, RC Alexander, A Reeve, ... The American journal of psychiatry 149 (6), 773-777, 1992 | 183 | 1992 |
| AZD3293: a novel, orally active BACE1 inhibitor with high potency and permeability and markedly slow off-rate kinetics S Eketjäll, J Janson, K Kaspersson, A Bogstedt, F Jeppsson, J Fälting, ... Journal of Alzheimer's Disease 50 (4), 1109-1123, 2016 | 140 | 2016 |
| Computerized cognitive remediation training for schizophrenia: an open label, multi-site, multinational methodology study NV Murthy, H Mahncke, BE Wexler, P Maruff, A Inamdar, M Zucchetto, ... Schizophrenia research 139 (1-3), 87-91, 2012 | 108 | 2012 |
| AZD3293: pharmacokinetic and pharmacodynamic effects in healthy subjects and patients with Alzheimer’s disease G Cebers, RC Alexander, SB Haeberlein, D Han, R Goldwater, ... Journal of Alzheimer's Disease 55 (3), 1039-1053, 2017 | 103 | 2017 |
| Principal component analysis of volatility smiles and skews C Alexander Available at SSRN 248128, 2001 | 99 | 2001 |
| Failure to detect Borna disease virus infection in peripheral blood leukocytes from humans with psychiatric disorders JA Richt, RC Alexander, S Herzog, DC Hooper, R Kean, S Spitsin, ... Journal of neurovirology 3 (2), 174-178, 1997 | 86 | 1997 |
| Minor physical anomalies in schizophrenia RC Alexander, S Mukherjee, J Richter, CA Kaufmann The Journal of nervous and mental disease 182 (11), 639-644, 1994 | 78 | 1994 |
| Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist P Bettica, G Nucci, C Pyke, L Squassante, S Zamuner, E Ratti, R Gomeni, ... Journal of Psychopharmacology 26 (8), 1058-1070, 2012 | 75 | 2012 |
| Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies E Ratti, P Bettica, R Alexander, G Archer, D Carpenter, G Evoniuk, ... Journal of psychopharmacology 27 (5), 424-434, 2013 | 73 | 2013 |
| Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3 … DK Burns, RC Alexander, KA Welsh-Bohmer, M Culp, C Chiang, J O’Neil, ... The Lancet Neurology 20 (7), 537-547, 2021 | 71 | 2021 |
| Biomarkers for response in major depression: comparing paroxetine and venlafaxine from two randomised placebo-controlled clinical studies L Carboni, DJ McCarthy, B Delafont, M Filosi, E Ivanchenko, E Ratti, ... Translational psychiatry 9 (1), 182, 2019 | 71 | 2019 |
| Medication nonadherence,“professional subjects,” and apparent placebo responders: overlapping challenges for medications development DJ McCann, NM Petry, A Bresell, E Isacsson, E Wilson, RC Alexander Journal of clinical psychopharmacology 35 (5), 566-573, 2015 | 70 | 2015 |
| A study of oral morphine preference in inbred mouse strains. WH Berrettini, R Alexander, TN Ferraro, WH Vogel Psychiatric genetics 4 (2), 81-86, 1994 | 70 | 1994 |
| Aspects of angiotensin action in the adrenal. Key roles for calcium and phosphatidyl inositol. ME Elliott, RC Alexander, TL Goodfriend Hypertension 4 (3_pt_2), 52-58, 1982 | 67 | 1982 |
| Monoamine oxidase inhibitors and tricyclic antidepressants: comparison of their cardiovascular effects. LS Goldman, RC Alexander, DJ Luchins The Journal of clinical psychiatry 47 (5), 225-229, 1986 | 65 | 1986 |
| Blood-CSF barrier permeability and central nervous system immunoglobulin G in schizophrenia DG Kirch, RC Alexander, RL Suddath, NM Papadopoulos, CA Kaufmann, ... Journal of Neural Transmission/General Section JNT 89, 219-232, 1992 | 60 | 1992 |
